Coherus Reveals US Launch Plans For Interchangeable Ranibizumab
Pricing Details Set Out Ahead Of 3 October Launch For Cimerli Biosimilar Version Of Lucentis
Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.
You may also be interested in...
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.
Coherus Biosimilar Used ‘Scientific Justification’ To Skip Switch Study, Still Get Interchangeability With Lucentis
Information on mechanism of action, pharmacokinetics, immunogenicity and toxicity convinced the US FDA there was no risk in terms of safety or diminished efficacy of switching between Cimerli and the reference product, Genentech’s eye drug Lucentis.